Aventis/Regeneron VEGF Colorectal Cancer Indication Part Of $500 Mil. Deal

Aventis and Regeneron are pursuing a colorectal indication for Regeneron's vascular endothelial growth factor trap after seeing positive results from Genentech's Phase III VEGF inhibitor Avastin

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet